c-Met/HGFR
c-Met/HGFR inhibitors target the Hepatocyte Growth Factor Receptor (c-Met), a tyrosine kinase involved in cellular processes such as growth, motility, and morphogenesis. c-Met signaling is implicated in cancer progression, metastasis, and resistance to therapies. Inhibiting c-Met can disrupt tumor growth and spread, making these inhibitors valuable in cancer research. At CymitQuimica, we offer c-Met/HGFR inhibitors to support your research in oncology, metastasis, and targeted cancer therapies.
Found 141 products of "c-Met/HGFR"
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
CSF1R-IN-2
CAS:CSF1R-IN-2 is an oral-active SRC, MET and c-FMS inhibitor (IC50s: 0.12 nM, 0.14 nM and 0.76 nM for SRC, MET and c-FMS respectively).Formula:C20H20FN7O2Purity:99.29%Color and Shape:SolidMolecular weight:409.42Pamufetinib
CAS:Pamufetinib (TAS-115) is a potent inhibitor of VEGFR and hepatocyte growth factor receptor (c-Met/HGFR)-targeted kinase.Formula:C27H23FN4O4SPurity:99.39%Color and Shape:SolidMolecular weight:518.56Ref: TM-T13108
1mg52.00€5mg101.00€10mg149.00€25mg244.00€50mg359.00€100mg510.00€200mg695.00€1mL*10mM (DMSO)127.00€SU 5616
CAS:SU 5616 (WAY-608241) regulates abnormal cell proliferation and modulates tyrosine kinase signaling.
Formula:C13H8ClNOSPurity:98.84%Color and Shape:SoildMolecular weight:261.73Rilotumumab
CAS:Rilotumumab (AMG 102) is an HGF-targeting antibody, inhibits HGF/MET signaling, and is used for CRPC and gastric cancer research.
Purity:SDS-PAGE:95% SEC-HPLC:97.51%Color and Shape:LiquidMolecular weight:145.2 kDac-Met inhibitor 1
CAS:c-Met inhibitor 1 is a c-Met receptor signaling pathway inhibitor, used for the treatment of cancer including glioblastoma, gastric, and pancreatic cancer.Formula:C17H14N8SPurity:98.77%Color and Shape:SolidMolecular weight:362.41Emibetuzumab
CAS:Emibetuzumab: potent humanized MET antibody, antitumor, inhibits HGF/MET pathways, for advanced prostate cancer research.Purity:SDS-PAGE:96.2%;SEC-HPLC:98.8%Color and Shape:LiquidMolecular weight:143.74 kDaBozitinib
CAS:Bozitinib (PLB-1001) (PLB-1001) is a highly selective inhibitor of the c-MET kinase with blood-brain barrier permeability.Formula:C20H15F3N8Purity:99.16%Color and Shape:SolidMolecular weight:424.38Ref: TM-T10585
1mg92.00€5mg205.00€10mg334.00€25mg595.00€50mg858.00€100mg1,198.00€200mg1,611.00€1mL*10mM (DMSO)227.00€Onartuzumab
CAS:Onartuzumab (MetMAb) is a humanized monoclonal antibody targeting c-MET, with antitumor effects by blocking HGF and signal transduction.Purity:97.3%Color and Shape:LiquidMolecular weight:146.99 kDaJNJ-38877618
CAS:JNJ-38877618 (OMO-1) is an effective and highly selective inhibitor of Met kinase (IC50s: 2 and 3 nM for wild type and mutant Met, respectively).Formula:C20H12F2N6Purity:98.84% - 99.74%Color and Shape:SolidMolecular weight:374.35Ref: TM-T15617
1mg59.00€5mg130.00€10mg200.00€25mg401.00€50mg557.00€100mg737.00€1mL*10mM (DMSO)144.00€Caveolin-1 (82-101) amide (human, mouse, rat)
CAS:Caveolin-1 (82-101) amide (human, mouse, rat), also known as Caveolin-1 scaffolding domain peptide, mitigates aging-related detrimental alterations in variousFormula:C124H170N28O29Purity:98%Color and Shape:SolidMolecular weight:2516.85c-Met ligand-Linker Conjugate 1
c-Met ligand-Linker Conjugate 1 is a Target Protein Ligand-Linker Conjugate that consists of a c-Met ligand and a PROTAC linker, capable of recruiting E3 ligase. This compound is used in the synthesis of PROTACc-Met degrader-5.Color and Shape:Odour SolidLMTK3-IN-1
CAS:Lmtk3-in-1 is a potent ATP-competitive lemur tyrosine kinase 3 (LMTK3) (Kd=2.5 μM) inhibitor that degrades LMTK3 through the ubiquitin proteasome pathway.Formula:C18H11F3N4OPurity:99.58%Color and Shape:SoildMolecular weight:356.3PROTAC c-Met degrader-1
CAS:PROTACc-Met degrader-1 (Compound Met-DD4) is an orally effective PROTAC degrader targeting c-Met with a DC50 of 6.21 nM. It inhibits the proliferation of c-Met-addicted MKN-45 cells with an IC50 of 4.37 nM and causes cell cycle arrest in the G0/G1 phase. In a xenograft mouse model using MKN-45 cells, PROTACc-Met degrader-1 demonstrates antitumor activity.Formula:C45H41FN10O5Color and Shape:SolidMolecular weight:820.87c-Met-IN-23
c-Met-IN-23 (Compound 12g) functions as a c-Met inhibitor with an IC50 of 0.052 μM against c-Met. It also inhibits the MDR1 and MRP1/2 pumps in cancerous HepG2 and BxPC3 cells. As such, c-Met-IN-23 serves as an anticancer agent.Formula:C16H13N7OMolecular weight:319.11816PROTAC c-Met degrader-2
CAS:PROTACc-Met degrader-2 (PROTAC2) is a c-Met degrader developed using PROTAC technology, with a DC50 value of 50 nM.Formula:C51H50F2N6O13Color and Shape:SolidMolecular weight:992.97Norleual
CAS:Angiotensin IV analog, potent HGF/c-MET inhibitor (IC50=3 pM), halts MDCK cell growth and invasion, AT4 antagonist, impairs LTP, antiangiogenic.
Formula:C41H58N8O7Purity:98%Color and Shape:SolidMolecular weight:774.95Fosgonimeton acetate
Fosgonimeton acetate is an agonist of hepatocyte growth factor (HGF).Formula:C29H49N4O10PPurity:98.01%Color and Shape:SolidMolecular weight:644.69Ref: TM-T39507L
1mg116.00€2mg160.00€5mg238.00€10mg353.00€25mg563.00€50mg758.00€100mg1,017.00€200mg1,359.00€BMS-777607
CAS:BMS-777607 is a Met-related inhibitor for c-Met, Axl, Ron and Tyro3.Formula:C25H19ClF2N4O4Purity:98.16% - 98.56%Color and Shape:SolidMolecular weight:512.89Ref: TM-T2658
2mg59.00€5mg86.00€10mg135.00€25mg251.00€50mg388.00€100mg690.00€200mg1,034.00€500mg1,550.00€PROTAC c-Met degrader-3
PROTACc-Met degrader-3 (Compound 22b) is a c-Met PROTAC degrader. It facilitates the ubiquitination and degradation of c-Met, with a DC50 of 0.59 nM in EBC-1 cells. PROTACc-Met degrader-3 is applicable in lung cancer research.Formula:C51H54N10O7Color and Shape:SolidMolecular weight:919.037PF-04217903 phenolsulfonate
CAS:PF-04217903 phenolsulfonate is a potent ATP-competitive inhibitor of c-Met kinase (Ki of 4.8 nM for human c-Met).Formula:C25H22N8O5SPurity:98%Color and Shape:SolidMolecular weight:546.56
